Oh, you should have waiting around for a few more months. It takes time to bed in companies when they have purchased other companies and are growing quickly at the same time. BTG also received a good write up in the Times newspaper and were rated a Good Buy today.
Of course, there are a number of other health care stocks that also offer excellent future potential. For example, Shire (LSE: SHP) (NASDAQOTH: SHPG.US) is forecast to double its sales by 2020 which, if met, would be a truly stunning result at a time when many of its pharmaceutical peers are struggling to even tread water. And, with Shire trading on a PEG ratio of 1.1, it still seems to offer excellent value for money.
Meanwhile, BTG (LSE: BTG) also offers excellent growth potential at a very enticing price. Its bottom line is forecast to rise by 27% next year and by a further 51% in the following year which, when combined with a P/E ratio of 36.6, equates to a PEG ratio of only 0.5. As such, it appears to be worth buying at the present time – even though its shares have already risen by 37% in the last year.
So, with Bioquell, Shire and BTG all having excellent growth potential, they appear to be well worth buying at the present time. Certainly, they may be more volatile than many of their UK-listed peers but, for long term investors, they could prove to be very rewarding investments.
"BTG plc 19th February (LSE:BTG) announces that application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 230,000 ordinary shares of 10 pence each under the BTG Performance Share Plan, to trade on The London Stock Exchange and to be admitted to The Official List. The new shares will, when issued, rank pari passu with the existing ordinary share capital of the Company. It is expected that admission will commence on 23 February, 2015."
All, BTG shares have risen well in the last year although they have flattened off recently. There have been some strong recommendations in the recent past, by various brokers/advisors/sites. What are peoples opinions, are the shares overpriced or are they still good value? Thanks
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.